Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice

Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice

Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent inflammatory response, and modulate gut barrier...

Full description

Bibliographic Details
Main Authors: Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
ankylosing spondylitis
rifaximin
gut microbiota
inflammatory response
intestinal epithelial barrier
Online Access:https://www.frontiersin.org/article/10.3389/fcimb.2019.00044/full

Internet

https://www.frontiersin.org/article/10.3389/fcimb.2019.00044/full

Similar Items